Hematological Disorder in Patients With Angiodysplasia

Sponsor
Assiut University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT06050798
Collaborator
(none)
55
36.4

Study Details

Study Description

Brief Summary

The study aim will be to assess the association between GIT angiodysplasia with any hematological disorders such as any specific coagulation disorders or anemia.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Von willebrand antigen

Detailed Description

Angiodysplasia is a vascular GI tract abnormality tortous thin walled blood vessels seen in mucosa and submucosa highly prone to rupture resulting in GIT bleeding and hematological disorders ,Impaired coagulation profile and anemia are main changes in angiodysplasia . (An overview of angiodysplasia: management and patient prospects,Grainne Holleran et al. Expert Rev Gastroenterol Hepatol. 2018 Sep.) Gastrointestinal angiodysplasia is a major cause of recurrent bleeding. Haemostatic abnormalities have been implicated in the haemorrhage from these common vascular lesions but their precise contribution remains to be established. (Gastrointestinal angiodysplasiaG Dodda et al. J Assoc Acad Minor Phys. 1997) Angiodyplasia and aortic stenosis are both conditions that are highly prevalent in elderly people and can often co-exist. Recent studies suggest that this association is related to subtle alterations in plasma coagulation factors . The von Willebrand factor is the strongest link between aortic stenosis and bleeding associated with gastrointestinal angiodysplasia. With an aging population, the disease burden of aortic stenosis and its association with angiodysplasia of the bowel makes this an incredibly under-diagnosed yet important condition. This association when dealing with elderly patients presenting either with unexplained anemia, gastrointestinal bleeding or with aortic stenosis should be considered. A high index of suspicion and appropriate diagnostic techniques followed by appropriate and prompt treatment could be life-saving. (Heyde Syndrome Complicated by Essential Thrombocythemia: A Case Report) Chronic hematologic diseases increase the fragility of blood cell components, leading to the progressive destruction of blood cells at the site of aortic stenosis . In this process, further destruction of large multimers of von Willebrand factor may lead to coagulation disorders and gastrointestinal bleeding, such as Heyde syndrome.

Study Design

Study Type:
Observational
Anticipated Enrollment :
55 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Hematological Disorder in Patients With Angiodysplasia
Anticipated Study Start Date :
Sep 20, 2023
Anticipated Primary Completion Date :
Sep 1, 2026
Anticipated Study Completion Date :
Oct 1, 2026

Outcome Measures

Primary Outcome Measures

  1. Hematological disorder in patients with angiodysplasia [Baseline]

    Von willebrand antigen change and anemia and impaired coagulation profile in angiodysplasia

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Adults (above 18 years) and elderly

  • Both genders

  • Admitted to GIT Unit with manifestations of GIT angiodysplasia diagnosed by upper endoscopy and Colonoscopy.

  • bleeding git symptoms

Exclusion Criteria:
  • other causes ofGIT bleeding

  • bleeding git ulcers

  • hematological disorder causing bleeding tendency ex hemophilia

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Assiut University

Investigators

  • Study Chair: AbdelHamid Mohamed AbdelHamid Aly, Assiut University
  • Study Chair: Nabeela Faiek Amin Mousa, Assiut University

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Lydia Mamdouh Sadek Botros, Assistant lecturer, Assiut University
ClinicalTrials.gov Identifier:
NCT06050798
Other Study ID Numbers:
  • Angiodysplasia
First Posted:
Sep 22, 2023
Last Update Posted:
Sep 28, 2023
Last Verified:
Sep 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 28, 2023